alexa Synthesis And QSAR Studies Of Anti-neoplastic Quinoxaline Pyrazole Conjugates
ISSN: 2161-0444

Medicinal chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
December 08-10, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Sarah H M Khairat, Shadia A Galal, Adel S Girgis, Fatma A F Ragab, Mamdouh M Ali, HamedI Ali and Hoda I El Diwani
Posters: Med Chem
DOI: 10.4172/2161-0444.S1.012
Abstract
Quinoxalines exhibit potential antitumor properties, which makes them an important basis for promising anticancer active targets. Many synthetic quinoxalines were reported as selective inhibitor of solid tumor with remarkable potency against multidrug resistant cancer cells. Additionally, the pyrazole ring is a prominent structural motif found in numerous pharmaceutically active compounds. Pyrazole framework plays an essential role in biologically active compounds and therefore represents an interesting template for combinatorial as well as medicinal chemistry. The present work, describes synthesis of novel quinoxalines, via functionalizing the hydrazino derivative 1 with either formylpyrazoles 3, or condensation with acetophenone followed by formylation and condensation with different amine, hydrazines, semicarbazide and/or thiosemicarbazide yielding quinoxaline-pyrazole conjugates 4. Many of the synthesized compounds 3, 4 revealed promising antitumor properties against HepG2 (liver) and MCF7 (breast) human tumor cell lines utilizing the in-vitro Sulfo-Rhodamine-B (SRB) standard method exhibiting potency close to or better than that of cisplatin, the standard reference. Statistically significant QSAR models describing the bioactivity were obtained employing CODESSA-Pro software.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords